Stem cell impregnated nanofiber stent sleeve for on-stent production and intravascular delivery of paracrine factors

Biomaterials

Volumn 52, Issue 1, 2015, Pages 318-326

  Hwang, Chao Wei ^a   Johnston, Peter V ^a   Gerstenblith, Gary ^a   Weiss, Robert G ^a   Tomaselli, Gordon F ^a   Bogdan, Virginia E ^a   Panigrahi, Asmi ^a   Leszczynska, Aleksandra ^a   Xia, Zhiyong ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY   (United States)

Author keywords

Coronary artery disease; Nanofiber; Paracrine factor; Peripheral artery disease; Stem cell

Indexed keywords

CELL CULTURE; DISEASE CONTROL; DISEASES; ENDOTHELIAL CELLS; FLOWCHARTING; MAMMALS; MORPHOLOGY; NANOFIBERS; STENTS; TISSUE REGENERATION;

CORONARY ARTERY DISEASE; HOST IMMUNE RESPONSE; HUMAN ENDOTHELIAL CELLS; MESENCHYMAL STEM CELL; PARACRINE; PERIPHERAL ARTERY DISEASE; PERMEABLE BARRIER; POLY LACTIC-CO-GLYCOLIC ACID;

STEM CELLS;

GLYCOLIC ACID; BIOMATERIAL; NANOFIBER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOLECULAR SIZE; NONHUMAN; PARACRINE SIGNALING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; STENT; THROMBOSIS; TISSUE REPAIR; UMBILICAL VEIN ENDOTHELIAL CELL; ALLOTRANSPLANTATION; ANGIOGRAPHY; ANIMAL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EQUIPMENT DESIGN; HUMAN; ISCHEMIA; MESENCHYMAL STROMA CELL; PATHOLOGY; PERMEABILITY; PIG;

ANIMALIA; SUIDAE;

ANGIOGRAPHY; ANIMALS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; MESENCHYMAL STROMAL CELLS; NANOFIBERS; PERMEABILITY; STENTS; SWINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84932618549     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.047     Document Type: Article

References (41)

1. Assmus B., Rolf A., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010, 3:89-96.
2. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
3. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAm Med Assoc 2012, 308:2369-2379.
4. Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012, 379:895-904.
5. Traverse J.H., Henry T.D., Pepine C.J., Willerson J.T., Zhao D.X., Ellis S.G., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAm Med Assoc 2012, 308:2380-2389.
6. Heldman A.W., DiFede D.L., Fishman J.E., Zambrano J.P., Trachtenberg B.H., Karantalis V., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAm Med Assoc 2014, 311:62-73.
7. Malliaras K., Makkar R.R., Smith R.R., Cheng K., Wu E., Bonow R.O., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). JAm Coll Cardiol 2014, 63:110-122.
8. Suncion V.Y., Ghersin E., Fishman J.E., Zambrano J.P., Karantalis V., Mandel N., et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial. Cir Res 2014, 114:1292-1301.
9. Nowbar A.N., Mielewczik M., Karavassilis M., Dehbi H.M., Shun-Shin M.J., Jones S., et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. Bmj 2014, 348. g2688.
10. Dimmeler S., Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circulation Res 2008, 102:1319-1330.
11. Terrovitis J.V., Smith R.R., Marban E. Assessment and optimization of cell engraftment after transplantation into the heart. Circulation Res 2010, 106:479-494.
12. Bonios M., Terrovitis J., Chang C.Y., Engles J.M., Higuchi T., Lautamaki R., et al. Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. JNuc Cardiol: Official Publ Am Soc Nucl Cardiol 2011, 18:443-450.
13. Huang X.P., Sun Z., Miyagi Y., McDonald Kinkaid H., Zhang L., Weisel R.D., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010, 122:2419-2429.
14. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Res 2008, 103:1204-1219.
15. Baraniak P.R., McDevitt T.C. Stem cell paracrine actions and tissue regeneration. Regen Med 2010, 5:121-143.
16. Chimenti I., Smith R.R., Li T.S., Gerstenblith G., Messina E., Giacomello A., et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circulation Res 2010, 106:971-980.
17. Gu M., Nguyen P.K., Lee A.S., Xu D., Hu S., Plews J.R., et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circulation Res 2012, 111:882-893.
18. Li T.S., Cheng K., Malliaras K., Smith R.R., Zhang Y., Sun B., et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. JAm Coll Cardiol 2012, 59:942-953.
19. Yeghiazarians Y., Zhang Y., Prasad M., Shih H., Saini S.A., Takagawa J., et al. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Molecular Therapy: J Am Soc Gene Ther 2009, 17:1250-1256.
20. Nguyen B.K., Maltais S., Perrault L.P., Tanguay J.F., Tardif J.C., Stevens L.M., et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. JCardiovasc Transl Res 2010, 3:547-558.
21. Sharma H.S., Das D.K. Role of cytokines in myocardial ischemia and reperfusion. Mediat Inflamm 1997, 6:175-183.
22. Oh B., Lee C.H. Advanced cardiovascular stent coated with nanofiber. Mol Pharm 2013, 10:4432-4442.
23. Wang J.B., Zhou B., Gu X.L., Li M.H., Gu B.X., Wang W., et al. Treatment of a canine carotid artery aneurysm model with a biodegradable nanofiber-covered stent: a prospective pilot study. Neurol India 2013, 61:282-287.
24. Mrowczynski W., Mugnai D., de Valence S., Tille J.C., Khabiri E., Cikirikcioglu M., et al. Porcine carotid artery replacement with biodegradable electrospun poly-e-caprolactone vascular prosthesis. JVasc Surg 2014, 59:210-219.
25. Comite P., Cobianchi L., Avanzini M.A., Zonta S., Mantelli M., Achille V., et al. Isolation and exvivo expansion of bone marrow-derived porcine mesenchymal stromal cells: potential for application in an experimental model of solid organ transplantation in large animals. Transplant Proc 2010, 42:1341-1343.
26. Peterbauer-Scherb A., van Griensven M., Meinl A., Gabriel C., Redl H., Wolbank S. Isolation of pig bone marrow mesenchymal stem cells suitable for one-step procedures in chondrogenic regeneration. JTissue Eng Regen Med 2010, 4:485-490.
27. Pittenger M.F. Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 2008, 449:27-44.
28. Bronckaers A., Hilkens P., Martens W., Gervois P., Ratajczak J., Struys T., et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacol Ther 2014, 143:181-196.
29. Ibrahim A.G., Cheng K., Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014, 2:606-619.
30. Bian S., Zhang L., Duan L., Wang X., Min Y., Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. JMol Med 2014, 92:387-397.
31. Fan M., Chen W., Liu W., Du G.Q., Jiang S.L., Tian W.C., et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res 2010, 13:429-438.
32. Kuraishi K., Iwata H., Nakano S., Kubota S., Tonami H., Toda M., et al. Development of nanofiber-covered stents using electrospinning: invitro and acute phase invivo experiments. JBiomedical Materials Res Part B Appl Biomater 2009, 88:230-239.
33. Dong Y. Nanofiber covered stent for vascular diseases 2009, [PhD Dissertation], National University of Singapore, Singapore.
34. Kim S.Y., Kim M., Kim M.K., Lee H., Lee D.K., Lee D.H., et al. Paclitaxel-eluting nanofiber-covered self-expanding nonvascular stent for palliative chemotherapy of gastrointestinal cancer and its related stenosis. Biomed Microdevices 2014 Dec, 16(6):897-904.
35. Lee C.H., Chang S.H., Lin Y.H., Liu S.J., Wang C.J., Hsu M.Y., et al. Acceleration of re-endothelialization and inhibition of neointimal formation using hybrid biodegradable nanofibrous rosuvastatin-loaded stents. Biomaterials 2014, 35:4417-4427.
36. Lee C.H., Lin Y.H., Chang S.H., Tai C.D., Liu S.J., Chu Y., et al. Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery. Int J Nanomedicine 2014, 9:311-326.
37. Blindt R., Vogt F., Astafieva I., Fach C., Hristov M., Krott N., et al. Anovel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. JAm Coll Cardiol 2006, 47:1786-1795.
38. den Dekker W.K., Houtgraaf J.H., Onuma Y., Benit E., de Winter R.J., Wijns W., et al. Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (GenousStent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Atherosclerosis 2011, 219:245-252.
39. Kang C.K., Lim W.H., Kyeong S., Choe W.S., Kim H.S., Jun B.H., et al. Fabrication of biofunctional stents with endothelial progenitor cell specificity for vascular re-endothelialization. Colloids Surfaces B Biointerfaces 2013, 102:744-751.
40. Klomp M., Beijk M.A., de Winter R.J. Genous endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Rev Med Devices 2009, 6:365-375.
41. Silber S., Damman P., Klomp M., Beijk M.A., Grisold M., Ribeiro E.E., et al. Clinical results after coronary stenting with the Genous Bio-engineered R stent: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. EuroIntervention: Journal of EuroPCR in collaboration with the working group on interventional cardiology of the european society of cardiology 2011, vol. 6:819-825.